Supernus Set To Launch Trokendi XR Against Generic Topamax

The Maryland CNS company got an FDA approval for its second epilepsy product and will begin marketing the drug before the close of the third quarter.

Supernus Pharmaceuticals Inc. got a green light from FDA to bring a second product to market for epilepsy patients Aug. 16. The Rockville, Md.-based company will be launching the once-daily extended release pill, Trokendi XR, before the end of the third quarter, CEO Jack Khattar said.

Trokendi XR is an extended-release version of topiramate, the generic drug that originally was sold under the brand name Topamax...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America